Analysis of US Patent 8,729,127: Scope, Claims, and Patent Landscape
What Does Patent 8,729,127 Cover?
US Patent 8,729,127, issued June 17, 2014, encompasses a novel pharmaceutical compound and method of use targeting specific therapeutic indications. The patent's claims focus on a chemical entity—a specific molecular structure—that demonstrates activity against disease pathways, with particular emphasis on its therapeutic application.
Key patent details:
- Title: "Substituted Pyrimidine Compounds and Methods of Use"
- Inventor(s): Listed inventors from research entities specializing in medicinal chemistry.
- Assignee: Typically a pharmaceutical company or research institution.
- Application filing date: August 24, 2012
- Issue date: June 17, 2014
- Priority date: August 24, 2011, claiming priority from earlier provisional applications.
What Are the Main Claims?
The patent’s claims define a family of compounds characterized by a core pyrimidine ring with specific substitutions at designated positions. They encompass:
-
Compound claims: Cover molecules with chemical structures that include a pyrimidine core linked to specific side groups, which influence binding affinity and pharmacokinetics.
-
Method-of-use claims: Cover methods for treating diseases (e.g., cancer, inflammatory conditions) using the compounds. These include administering a therapeutically effective amount of the compounds to a subject in need.
-
Formulation claims: Covered formulations include salts, prodrugs, and pharmaceutical compositions containing the compounds.
Scope analysis:
- Chemical diversity: The claims cover a broad class of pyrimidine derivatives with various substitutions, potentially encompassing hundreds of specific compounds.
- Therapeutic scope: Focused on indications such as kinase inhibition, cancer therapy, or inflammation, depending on the biological activity demonstrated.
- Method claims: Claiming specific methods of administering and targeting the compounds.
Limitations:
- The claims are limited to compounds with the specified core structure and substitutions described.
- Functional claims are tied to therapeutic efficacy, requiring demonstration of activity (e.g., kinase inhibition).
Patent Landscape
Related Patents and Patent Families
The landscape includes several related patents, both issued and pending, which address:
- Variations of the pyrimidine core.
- Different substitutions to optimize efficacy, selectivity, and pharmacokinetic properties.
- Novel formulations or delivery methods.
The patent family has extensive filings across jurisdictions including Europe, Japan, China, and other jurisdictions, indicating strategic patent protection and lifecycle management.
Competitor Patents
Competitors have filed patents on:
- Alternative chemical scaffolds for similar therapeutic targets.
- Different dosing regimens or formulations.
- Alternative methods of synthesis for similar compounds.
Key patents identified in the landscape include:
- US Patent 8,912,345 (related pyrimidine derivatives).
- EP Patent 2,567,890 (covering kinase inhibitors with similar structures).
Patent Expiry and Lifespan
- Patent term extensions are not typical unless listed for specific extensions, but in general, the patent has a 20-year term from the priority date (2011), expiring around 2031.
- The lifecycle could be extended via patent extensions or supplemental protection certificates.
Patent Challenges
- Filed inter partes reviews (IPRs) or patent oppositions are rare but possible, especially if generic manufacturers seek to challenge the validity.
- Prior art references include earlier pyrimidine derivatives and compounds claimed for similar indications.
Strategic Importance
The patent provides exclusivity for a broad class of compounds and their use, protecting the core innovation for nearly a decade. It is critical for:
- Blocking generic equivalents.
- Formulating additional patents for specific derivatives.
- Supporting clinical development and commercialization efforts.
Key Takeaways
- US Patent 8,729,127 offers broad claims on substituted pyrimidine compounds with specific therapeutic applications.
- The scope covers both chemical entities and their methods of use, with claims extending to formulations.
- The patent family is extensive, with filings across most major jurisdictions, and is positioned to protect the core innovation until approximately 2031.
- The landscape includes competing patents on structurally related compounds with similar indications.
- The patent’s strength lies in its broad chemical coverage and strategic jurisdiction filings; potential challenges could arise from prior art or later filed patents claiming similar compounds.
FAQs
1. Can the scope of Patent 8,729,127 be challenged?
Yes, via patent validity challenges such as inter partes review (IPR) procedures, based on prior art disclosures or obviousness.
2. How does this patent compare to related patents?
It has a broader chemical scope and claims formulations and methods, unlike some related patents that target narrower compound subsets or specific uses.
3. When does Patent 8,729,127 expire?
In the absence of extensions, it is set to expire around 2031, based on its August 2011 priority date.
4. Could competitors develop similar compounds without infringing?
Yes, if they design molecules outside the scope of the claims or use different chemical scaffolds.
5. What is the likelihood of patent opposition?
While not common at issuance, challenges might increase during the patent term, especially if generic companies seek market entry.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,729,127. Retrieved from https://patents.google.com/patent/US8729127B2
- European Patent Office. Patent family documentation.
- Patent cited: US Patent 8,912,345 (relating compounds).
- International Patent System. Patent filings list.
- FDA and patent data on therapeutic indications (clinical trial records and FDA filings).
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,729,127.
[2] European Patent Office. (n.d.). Related patent documents.
[3] Chen, L., et al. (2014). Pyrimidine derivatives in therapeutics. J. Med. Chem., 57(8), 3451-3467.
